Literature DB >> 34704188

Precision Treatments in Epilepsy.

Scott Demarest1, Amy Brooks-Kayal2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34704188      PMCID: PMC8608958          DOI: 10.1007/s13311-021-01147-x

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   6.088


× No keyword cloud information.
  13 in total

1.  ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology.

Authors:  Ingrid E Scheffer; Samuel Berkovic; Giuseppe Capovilla; Mary B Connolly; Jacqueline French; Laura Guilhoto; Edouard Hirsch; Satish Jain; Gary W Mathern; Solomon L Moshé; Douglas R Nordli; Emilio Perucca; Torbjörn Tomson; Samuel Wiebe; Yue-Hua Zhang; Sameer M Zuberi
Journal:  Epilepsia       Date:  2017-03-08       Impact factor: 5.864

Review 2.  Diagnostic Considerations in the Epilepsies-Testing Strategies, Test Type Advantages, and Limitations.

Authors:  Wei-Liang Chen; Heather C Mefford
Journal:  Neurotherapeutics       Date:  2021-09-16       Impact factor: 6.088

Review 3.  Clinical Trial Design for Disease-Modifying Therapies for Genetic Epilepsies.

Authors:  Dylan C Brock; Scott Demarest; Tim A Benke
Journal:  Neurotherapeutics       Date:  2021-09-30       Impact factor: 6.088

Review 4.  Novel Approaches to Prevent Epileptogenesis After Traumatic Brain Injury.

Authors:  Chris G Dulla; Asla Pitkänen
Journal:  Neurotherapeutics       Date:  2021-09-30       Impact factor: 6.088

Review 5.  Screening Platforms for Genetic Epilepsies-Zebrafish, iPSC-Derived Neurons, and Organoids.

Authors:  Aleksandr Shcheglovitov; Randall T Peterson
Journal:  Neurotherapeutics       Date:  2021-09-30       Impact factor: 6.088

Review 6.  Haploinsufficiency, Dominant Negative, and Gain-of-Function Mechanisms in Epilepsy: Matching Therapeutic Approach to the Pathophysiology.

Authors:  Gemma L Carvill; Tyler Matheny; Jay Hesselberth; Scott Demarest
Journal:  Neurotherapeutics       Date:  2021-10-14       Impact factor: 6.088

Review 7.  Natural History Studies and Clinical Trial Readiness for Genetic Developmental and Epileptic Encephalopathies.

Authors:  Elizabeth E Palmer; Katherine Howell; Ingrid E Scheffer
Journal:  Neurotherapeutics       Date:  2021-10-27       Impact factor: 6.088

Review 8.  Novel Therapeutics for Neonatal Seizures.

Authors:  Julie M Ziobro; Krista Eschbach; Renée A Shellhaas
Journal:  Neurotherapeutics       Date:  2021-08-12       Impact factor: 6.088

Review 9.  Emerging Gene and Small Molecule Therapies for the Neurodevelopmental Disorder Angelman Syndrome.

Authors:  Nycole A Copping; Stephanie M McTighe; Kyle D Fink; Jill L Silverman
Journal:  Neurotherapeutics       Date:  2021-09-15       Impact factor: 7.620

Review 10.  Gene Editing and Modulation: the Holy Grail for the Genetic Epilepsies?

Authors:  Jenna C Carpenter; Gabriele Lignani
Journal:  Neurotherapeutics       Date:  2021-07-07       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.